Tokyo and Indianapolis, November 4 (ots/PRNewswire) - - Investigational compound reduces risk of major cardiovascular events by 19 percent, significantly improves net clinical benefit despite increased bleeding In the pivotal Phase III head-to-head TRITON TIMI-38 clinical trial, the investigational ...
Boston, November 2 (ots/PRNewswire) - - This Landmark Study Also Shows Response at 12 Weeks is a Powerful Predictor of Eventual Treatment Success. Roche today announced final results from the REPEAT study, which demonstrate that treatment with once-weekly PEGASYS(R) (peginterferon alfa-2a(40KD)) and ...
Basel, Switzerland, November 2 (ots/PRNewswire) - - Roche Progresses R1626 Into Phase IIb Study Called POLI 1 R1626, one of Roche's new investigational drugs for hepatitis C (HCV), has shown promising antiviral efficacy when given in combination with PEGASYS(R) (peginterferon alfa-2a (40KD)) and COPEGUS(R) (ribavirin), according to results being presented at ...
Brussels (ots/PRNewswire) - First study to investigate the protective effect of a lipid-lowering agent on diabetic eye disease to be published on-line in Lancet, Tuesday, 6th November 2007 Diabetic eye disease (called diabetic retinopathy) is the leading cause of vision loss in adults - affecting about 25 ...
San Diego, and Indianapolis, and Cambridge, Massachusetts (ots/PRNewswire) - - U.S. New Drug Application Filing Planned by the End of the First Half of-2009 - Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced positive results ...
Amsterdam (ots/PRNewswire) - Avantium Technologies announced today that they have signed an agreement with CRI/Criterion Inc. to enable the sale and delivery of multiple Avantium Flowrence(TM) systems. CRI/Criterion, a catalyst technology company within the Royal Dutch Shell group, is a part of a group of affiliated companies that are leading providers of catalysts, process technologies and catalyst services for a ...
Paris (ots/PRNewswire) - - Novel Compound Offers Hope to Patients not Adequately Responding to Laxative Treatment Data presented for the first time today at the international gastroenterology meeting UEGW (United European Gastroenterology Week) confirm the effectiveness and safety of RESOLOR(R) ...
Irvine, California (ots/PRNewswire) - IsoTis, Inc. (NASDAQ: ISOT) ("IsoTis"), an orthobiologics company, today announced that, at the special meeting of stockholders re-convened earlier today, IsoTis stockholders have approved the acquisition of IsoTis by Integra LifeSciences Holdings Corporation (NASDAQ: IART) ("Integra") pursuant to an agreement and plan of merger dated as of August 6, 2007. The acquisition is ...
Toronto (ots/PRNewswire) - Dalton Medicinal Chemistry Partners, the Medicinal Chemistry arm of Dalton Pharma Services, announces that it has achieved a targeted milestone in its Medicinal Chemistry agreement with Boehringer Ingelheim (Canada) Ltd. The milestone achievement triggered payment of an undisclosed ...
Basel, Switzerland (ots/PRNewswire) - A new study on pain published today has found that subcutaneous (SC) injections of the new renal anaemia therapy MIRCERA is associated with significantly less pain immediately after injection than SC darbepoetin-alfa (Aranesp).(1) These findings are important because to date there has been minimal data regarding SC injection ...
Irvine, California (ots/PRNewswire) - - Less Than 40,000 Additional "FOR" Votes Required for Integra Merger IsoTis, Inc. (NASDAQ: ISOT) ("IsoTis"), an orthobiologics company, today announced that it has adjourned its special meeting of stockholders again, to Monday, October 29, 2007, to approve the acquisition of IsoTis by Integra LifeSciences Holdings Corporation (NASDAQ: IART) ("Integra") pursuant to an ...
Irvine, California (ots/PRNewswire) - - Less than 100,000 Additional "FOR" Votes Required for Integra Merger IsoTis, Inc. (NASDAQ: ISOT) ("IsoTis"), an orthobiologics company, today reported that less than 100,000 votes "FOR" are needed to approve the acquisition of IsoTis by Integra LifeSciences Holdings Corporation (NASDAQ: IART) ("Integra") pursuant to an agreement and plan of merger dated as of August 6, ...
Madrid, Spain (ots/PRNewswire) - - For Non-U.S. Media New data from the combined RESIST studies (RESIST-1 and RESIST-2) show that Aptivus(R) (tipranavir), used with Norvir (ritonavir), provides a superior and durable treatment response for up to three years in treatment- experienced HIV patients versus ...
Irvine, California (ots/PRNewswire) - - Less Than 350,000 Additional Votes "FOR" Required for Integra Merger IsoTis, Inc. (NASDAQ: ISOT) ("IsoTis"), an orthobiologics company, today announced that it has adjourned the special meeting of stockholders again, to October 26, 2007, to approve the acquisition of IsoTis by Integra LifeSciences Holdings Corporation (NASDAQ: IART) ("Integra") pursuant to an agreement ...
London (ots/PRNewswire) - Data from two observational studies of over 470,000 patients taking statins in routine clinical practice investigating the incidence of cardiovascular events in patients taking CRESTOR(TM) (rosuvastatin) and other statins were presented today at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 10th Annual ...
Amsterdam (ots/PRNewswire) - - Not for release, distribution or publication into or in the United States, Australia, Canada and Japan. - Positive Results With Next Generation Biofuels Trigger IPO Plans Avantium, a leading technology company in the area of advanced high-throughput R&D, announces its intention to raise new funds through an initial public offering (the "IPO") and to apply for a listing on ...
Amsterdam (ots/PRNewswire) - - Engine Test Demonstrates Potential of "Furanics" Avantium announced today breakthrough results of the first engine tests of its novel biofuel. The technology company is developing next generation biofuel with superior economics and properties in comparison to current biofuels. By applying its advanced high-throughput R&D technology Avantium develops since a number of years a ...
Paris (ots/PRNewswire) - Sanofi-aventis announced today that the Japanese Ministry of Health, Labor and Welfare (MHLW) has granted approval for a Supplemental New Drug Application (sNDA) for the indication of "Acute coronary syndrome (unstable angina pectoris, non-ST elevation myocardial infarction) for which ...
Basel, Switzerland (ots/PRNewswire) - - MAXIMA Findings in the Lancet Affirm Ability to Maintain Haemoglobin Levels With Less Frequent Dosing A pivotal study published today in the Lancet has shown that dialysis patients can be effectively switched from frequently dosed anaemia drugs to an innovative new ...
Calgary, Canada (ots/PRNewswire) - - Canadian Biotechnology Company has now Established Commercial Levels of Both Native Apo AI and Apo AI(Milano) variant in Safflower Seed Lines SemBioSys Genetics Inc. (TSX:SBS), a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases , today announced that it has ...
Gaithersburg, Maryland and Hilden, Germany (ots/PRNewswire) - The first randomized, controlled study in North America of HPV testing as a stand-alone screen concluded that it is almost 40 percent more accurate than traditional cytology (the Pap "smear") in identifying women with advanced cervical disease, according to a report published today in The New England ...
Perimeter Institute for Theoretical Physics
Waterloo, Canada (ots/PRNewswire) - Canada's Perimeter Institute for Theoretical Physics (PI) is pleased to announce that renowned scientist Leonard Susskind has joined its Faculty as an Associate Member. Professor Susskind is widely recognized as one of the most highly creative researchers in the field of ...
Basel, Switzerland (ots/PRNewswire) - Ten abstracts providing new analyses of data from six major Phase III renal anaemia studies for MIRCERA(R) will be published/presented at the upcoming 40th Annual Meeting of the American Society of Nephrology (ASN) in San Francisco on 2 - 5 November. Among the highlights will be new analyses from 'maintenance' studies ...
Shire Pharmaceuticals Group Plc
Philadelphia (ots/PRNewswire) - At the U.S. Food and Drug Administration's (FDA's) Cardiovascular and Renal Drugs Advisory Committee meeting today, the majority of members voted to recommend the use of phosphate binders, including Shire Pharmaceuticals' non-calcium FOSRENOL(R) (lanthanum carbonate), to treat ...
Amsterdam (ots/PRNewswire) - Avantium, a leading technology company servicing the oil, chemicals and pharmaceutical industries, announces the three-year extension of the strategic research collaboration with BP, one of the world's largest energy companies. Avantium provides innovative, high value-added R&D services and tools to the energy, chemicals and pharmaceutical industries, and has a long standing ...
Irvine, California (ots/PRNewswire) - - Conference Calls to Answer Questions About Stockholder Meeting October 23 IsoTis, Inc. (NASDAQ: ISOT) ("IsoTis"), an orthobiologics company, today announced the interim tabulation results of the special stockholders meeting held on October 11, 2007 and adjourned to October 23, 2007. Prior to October 11, 2007, approximately 2,555,000 shares, 36 percent of the shares ...
Vienna, Austria (ots/PRNewswire) - Valdoxan(R) (agomelatine), the first melatonergic antidepressant, is an effective, long-term treatment for Major Depressive Disorder (MDD) according to new data presented today at the European College of Neurospsychopharmacology (ECNP) annual congress. The new international ...
Calgary, Canada (ots/PRNewswire) - - Novel ApoA-I/HDL Raising Drug, RVX-208, to be Featured in Oral Presentation Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce that tommorrow it is making an oral presentation highlighting key scientific data of its lead clinical molecule, RVX-208, at the International Atherosclerosis Society (IAS) Workshop on HDL. The presentation titled "A novel drug that ...
Irvine, California (ots/PRNewswire) - IsoTis, Inc. (NASDAQ: ISOT) ("IsoTis"), an orthobiologics company, today announced that it has adjourned the special meeting of stockholders it called to approve the acquisition of IsoTis by Integra LifeSciences Holdings Corporation (NASDAQ: IART) ("Integra") pursuant to an agreement and plan of merger dated as of August 6, 2007. The special meeting of stockholders was held at ...
Leuven, Belgium (ots/PRNewswire) - - EUFAMI Survey Shows Carers Across Europe Believe in Remission as a Realistic Treatment Goal for Many People Living With Schizophrenia A large majority of families who care for someone with schizophrenia are confident that many people with the disease can lead ...